DERM
Journey Medical Corp
+0.25 (+3.50%)7.55USD50.5K成交股數207M市值–本益比(近四季)3.1股價營收比+18.9%營收年增(近四季)2026-11-11下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 17.8M+19% | 15.9M+21% | 16.1M+10% | 17.0M+15% | 15.0M+15% | 13.1M-14% | 14.6M-4% | 14.9M-12% | 13.0M | 15.3M | 15.3M | 17.0M |
| 營業成本 | 6.1M | 6.2M | 5.4M | 5.8M | 4.9M | 4.8M | 5.3M | 6.5M | 6.8M | 2.2M | 6.4M | 7.8M |
| 毛利 | 11.7M+16% | 9.7M+16% | 10.6M+14% | 11.3M+36% | 10.1M+62% | 8.3M-36% | 9.3M+6% | 8.3M-10% | 6.2M | 13.0M | 8.9M | 9.2M |
| 毛利率 | 65.6% | 60.9% | 66.1% | 66.2% | 67.1% | 63.5% | 63.9% | 56.0% | 47.7% | 85.3% | 57.9% | 54.2% |
| 研發費用 | 54K | – | – | 287K | – | 39K | 842K | 913K | 7.9M | 1.5M | 2.2M | 1.8M |
| 銷售管理費用 | 10.9M | 10.1M | 9.9M | 12.1M | 11.9M | 10.6M | 11.4M | 10.3M | 8.4M | 9.8M | 8.6M | 12.1M |
| 營業利益 | 456K-116% | −1.5M-55% | −443K-85% | −1.5M-48% | −2.9M-71% | −3.3M+58% | −2.9M-117% | −2.9M-62% | −10.1M | −2.1M | 17.2M | −7.7M |
| 營業利益率 | 2.6% | -9.4% | -2.8% | -9.0% | -19.2% | -25.3% | -19.8% | -19.7% | -77.4% | -13.8% | 112.9% | -45.1% |
| 稅後淨利 | −312K-92% | −2.2M-45% | −1.2M-48% | −2.3M-31% | −3.8M-64% | −4.1M+90% | −2.4M-114% | −3.4M-60% | −10.4M | −2.1M | 16.8M | −8.4M |
| 淨利率 | -1.7% | -14.0% | -7.8% | -13.6% | -25.3% | -31.0% | -16.3% | -22.6% | -80.1% | -14.0% | 109.9% | -49.3% |
| 稀釋 EPS | -0.01-94% | -0.08-56% | -0.04-67% | -0.09-47% | -0.16-70% | -0.18-1000% | -0.12-115% | -0.17-63% | -0.53 | 0.02 | 0.80 | -0.46 |
| 稀釋股數 | 27.5M | 27.3M | 24.5M | 25.0M | 23.3M | 22.6M | 20.5M | 20.0M | 19.8M | 18.2M | 21.0M | 18.0M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 25.6M | 27.2M | 24.1M | 24.9M | 20.3M | 21.1M | 22.5M | 23.9M | 24.1M | 27.4M | 24.7M | 8.2M |
| 應收帳款 | 36.2M | 25.0M | 29.8M | 18.0M | 15.6M | 18.0M | 10.7M | 10.5M | 9.8M | 15.2M | 8.0M | 16.7M |
| 存貨 | 8.2M | 9.3M | 9.6M | 11.8M | 12.9M | 12.5M | 11.8M | 9.7M | 10.6M | 10.2M | 11.0M | 12.2M |
| 總資產 | 98.4M | 91.5M | 94.6M | 85.2M | 81.2M | 85.0M | 64.0M | 65.2M | 66.6M | 76.8M | 65.9M | 69.7M |
| 有息負債 | 20.5M | 22.9M | 25.3M | 19.5M | 21.4M | 23.1M | 19.8M | 19.7M | 14.7M | 14.6M | 0.00 | 9.9M |
| 總負債 | 66.2M | 60.7M | 62.7M | 59.3M | 61.9M | 63.4M | 53.1M | 53.9M | 53.6M | 56.5M | 48.5M | 69.7M |
| 股東權益 | 32.1M | 30.8M | 31.9M | 25.9M | 19.2M | 21.5M | 10.9M | 11.3M | 13.0M | 20.4M | 17.4M | 5K |
| 負債比 | 67.3% | 66.3% | 66.3% | 69.6% | 76.3% | 74.6% | 82.9% | 82.7% | 80.5% | 73.5% | 73.6% | 100.0% |
| 淨現金(現金 − 有息負債) | 5.2M | 4.3M | −1.2M | 5.4M | −1.1M | −2.0M | 2.7M | 4.2M | 9.4M | 12.8M | 24.7M | −1.7M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 2.9M-203% | – | – | – | −2.8M | – | – | −5.0M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 61.9M
| Dermatological | 61.9M | 100.0% | +10.2% |
|---|
產品／服務2025 年度 · 61.2M
| Qbrexza | 25.0M | 40.8% | -0.4% |
|---|---|---|---|
| Emrosi | 14.7M | 24.1% | – |
| Accutane | 12.9M | 21.0% | -33.6% |
| Foam Franchise Products Amzeeq Zilxi | 5.9M | 9.6% | -11.9% |
| Other Legacy | 2.7M | 4.5% | -30.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 61.2M | +11.1% | −11.4M | -18.7% | -0.47 | – |
| FY2024 | 55.1M | -7.6% | −14.7M | -26.6% | -0.72 | −24.1M |
| FY2023 | 59.7M | -16.0% | −3.9M | -6.5% | -0.21 | 240K |
| FY2022 | 71.0M | +12.5% | −29.6M | -41.7% | -1.69 | −33.5M |
| FY2021 | 63.1M | +41.8% | −44.0M | -69.7% | -4.32 | – |
| FY2020 | 44.5M | – | 5.3M | 11.9% | 0.49 | – |